The qualitative PCR-based assessment of TGF-β1, Arg1, NOS2, IL-10, TNFα, IL-1β, IL-12a, and Ido1 mRNA expression in cells of the tumor node, conducted on Days 15 and 16 since the treatment initiation, indicated that the inclusion of GcMAF-RF into the treatment course results in suppressing the synthesis of anti-inflammatory cytokine mRNAs. The gene discussed is TGFB1; the disease is neoplasm.